• linkedin
  • Increase Font
  • Sharebar

    Uro Pipeline: Supplemental application submitted for advanced RCC treatment

     

    Application submitted for injectable OAB treatment

    Allergan has submitted an investigational new drug application for UroGen Pharma Ltd.’s RTGel in combination with onabotulinumtoxinA (Botox) for treatment of overactive bladder, UroGen announced. UroGen granted an exclusive worldwide license to Allergan in October 2016, which allows Allergan to develop and commercialize pharmaceutical products that contain RTGel and clostridial toxins, including onabotulinumtoxinA. RTGel has thermosensitive properties that enable it to convert from a liquid state when cold into a gel when it reaches body temperature. This allows for increased residence time of drugs when mixed with the gel and instilled in the bladder. OnabotulinumtoxinA is approved as a second-line therapy for OAB in patients who do not respond to anticholinergic medications.

    Study: Agent helps control pain in IC/BPS patients

    PureTech Health plc presented data for its product candidate, ALV-107, to control pain related to interstitial cystitis/bladder pain syndrome. Study data showed durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose (ALV-107, 16 mg/kg; conventional lidocaine, 16 mg/kg). In the study, pain levels were measured by the mean nociceptive threshold and the levels were statistically indistinguishable between the pain-free baseline and the ALV-107-treated group. The conventional lidocaine-treated group was only statistically indistinguishable from the pain-free baseline at 2 hours post-treatment. ALV-107 uses PureTech’s proprietary Alivio inflammation-targeting technology, which is designed to adhere selectively to inflamed tissue and remain adhered to deliver medication based on levels of inflammation and potentially minimize exposure to healthy tissue.

    Next: Study supports technology's use in chaacterizing UTUC lesions

    Ben Schwartz
    Ben Schwartz is Associate Editor, Contemporary OB/GYN.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll